Newsletters

AIPES Newsletter 2016

A word from the President :

aipes 2016 ico
"Dear friends,

As we count down to the end of the year, I would like to thank you on behalf of the executive team of AIPES all for your contributions and your support in 2016. As our newsletter reveals, this year has been busy and successful.

Nuclear medicine is flourishing with new initiatives and innovations. The same enthusiasm is driving our activities in AIPES: our role is growing and we are becoming more visible in public policy.

We had many memorable moments in 2016, and I would like to single out our Symposium in Brussels in September, which was generously supported by the European Parliament, and generated wonderful feedback. And as you will read below, our working groups, the driving force of the association, have launched a flurry of new initiatives." (...)
click here to read more




The 2015 newsletter: Focus on our Target !

aipesnewsletter iconNuclear Medicine is still on the crest of a wave in spite of the healthcare system turmoil.

New PET tracers and new Technetium tracers have increased the role and involvement of NM in clinical oncology, neurol­ogy, cardiology - and not only in these three areas; indeed, many clinical trials rely on NM thanks to its functional nature. In addition, therapy is making slow but significant progress with the arrival of alpha emitters and with new trial launches where antibodies and peptides are labelled with beta emitters.

And finally, Nuclear Medicine is developing into a Personalized Medicine pillar via the fast-growing “Theranostic” approach and the imaging “companion drug” concept. All of it is achieved thanks to the Academic World, and thanks to you, the Industry.

Since last year and with the energy of all the people committed to support AIPES actions, we have pursued our hard work in promoting the advantages of our industry; in particular, we have strived to give prominence to our point of view in the legisla­tor’s mind. We wish to warmly thank everyone in the association again for their hard work and involvement.

Important organizations, such as the European institutions and the OECD, recognize AIPES as a key stakeholder in their ef­forts to extensively address the main issues encountered by our industry, investment and reimbursement, and also by govern­ments, the HEU supply … read more.

La place de la médecine nucléaire dans la médecine du XXIe siècle.

Guy Turquet de Beauregard, président AIPES,
RGN - Revue Générale Nucléaire, août 2012

guy articleL’enjeu d’une médecine personnalisée, qui vise à prévoir, détecter, suivre et guérir les pathologies et qui se fonde sur le caractère individuel de chaque patient, devient de plus en plus fort en Europe comme aux Etats-Unis. Comme outil de diagnostic basé sur la physiologie, la médecine nucléaire avec ses nouveaux médicaments radioactifs et ses puissants outils d’imagerie offre un potentiel essentiel à cette approche.
cliquez ici pour télécharger l’article complet










LeMonde

Nuclear Medicine: The Osiris Reactor Must Be Prolonged Article published on 27th November, 2013 in "Le Monde" by Guy Turquet de Beauregard, President of the AIPES

At the forthcoming Comité à l’Energie Atomique (Atomic Energy Committee), the decision France has to make will impact every country in Europe, including itself:
Can the alt of research reactor Osiris, planned for late 2015, be postponed by 3 years – today this reactor supplies Europe, and even beyond, with radioisotopes essential for Nuclear Medicine?

What is the context? Several major reasons lead modern medicine towards a personalized medicine approach: too many negative responses to treatments, huge health insurance deficits, high development costs for new medication and, overall, major biological breakthroughs. Henceforth, in this perspective, modern medicine greatly relies on medical imaging. There exist two types of imaging: on one hand, Morphological Imaging using MRI techniques (Magnetic Resonance Imaging), Ultrasounds or Scan X, and on the other hand Functional Imaging using Nuclear Medicine, which produces an image of the physiological functioning of the organs or pathologies to be diagnosed. These two imaging types are therefore perfectly complementary.

Nuclear Medicine is based on the incorporation of a radioactive atom in a molecule, specific of a pathology. Thus emitting a nuclear radiation, these biomolecules become medication; when injected into patients they produce images called “scintigraphic” to visualize the pathological “functionality”. Nuclear Medicine routinely uses imaging to evaluate heart failure, identify and localize tumors or metastases, or again assess the development stage of neurodegenerative diseases.

What are the stakes?
Nuclear Medicine mainly uses a radioelement, technetium Tc 99m, from fission products generated in a limited number of reactors over the world. Examinations using technetium Tc 99m represent nearly three-quarters of Nuclear Medicine diagnosis examinations (over 30 million per year worldwide, 8.5 million per year in Europe).
The Osiris reactor in Saclay, France is currently one of five reactors in Europe supplying technetium Tc 99m on a weekly basis. There are only three other reactors in the world capable of this. In terms of production, medical radioisotopes are similar to electricity insofar as they cannot be stockpiled (technetium Tc 99m has a half-life of 6 hours). Therefore, reactors that break down or are stopped for maintenance purposes require higher production levels than necessary for daily use. The worldwide capacity from all reactors currently represents approx. 170% of needs.